-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotiabank Maintains Sector Outperform on Castle Biosciences, Lowers Price Target to $40

Benzinga·05/21/2025 15:50:55
Listen to the news
Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and lowers the price target from $44 to $40.